WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Nanotechnology in development of drug delivery system

Dhobale Suvarna[1*], Rasve Vishal[2], Dr.Sayyed Gaffar[3], Dr. Garje Sanjay[4]

SAJVPM's College of pharmaceutical Science And Research Centre Kada (Beed) India
Corresponding Author: *

ABSTRACT:

Nanotechnology has renewed the field of drug delivery by enabling precise and targeted therapeutic interventions. This approach utilizes nanoparticles, typically ranging from 1 to 100 nanometers, to enhance drug delivery efficiency, improve bioavailability, and reduce toxicity. Nanoparticles can be engineered to protect drugs from degradation, allow controlled release, and facilitate targeted delivery to specific tissues or cells, thereby minimizing side effects. Various types of nanocarriers, such as liposomes, dendrimers, polymeric nanoparticles, and metallic nanoparticles, have been explored for delivering a wide range of therapeutic agents, including chemotherapeutics, peptides, and genetic materials. The incorporation of targeting ligands and stimuli-responsive mechanisms further enhances the potential for precision medicine. While nanotechnology holds great promise in transforming drug delivery, challenges such as nanoparticle toxicity, scalability, and regulatory hurdles need to be addressed. Ongoing research in this field continues to push the boundaries of innovation, offering new hope for treating diseases like cancer, neurological disorders, and infectious diseases.

Keywords: Nanoparticles, Targeted drug delivery, cancer therapy, liposomes.

Introduction:

Nanotechnology is the manipulation of matter on an atomic or molecular scale, has emerged as a groundbreaking approach in various fields, particularly in medicine. In drug delivery systems (DDS), nanotechnology plays a crucial role by enabling the development of more efficient, targeted, and controlled drug release mechanisms. These advancements are reshaping the way pharmaceuticals are administered, improving therapeutic outcomes, and minimizing side effects. Nanoparticles, nanocarriers, and nanoscale materials have the potential to enhance drug bioavailability, stability, and specificity, making them ideal candidates for delivering drugs directly to the targeted site of action. Unlike conventional drug delivery methods, which often suffer from poor targeting and premature drug release, nanotechnology-based systems can be engineered to respond to specific biological environments, such as pH changes or enzyme activity, ensuring that drugs are released only when and where they are needed most. This integration of nanotechnology into drug delivery holds promise for treating various diseases, including cancer, neurological disorders, and chronic conditions, by improving the precision and effectiveness of drug delivery, reducing toxicity, and increasing patient compliance. As research continues, the potential for nanotechnology to revolutionize healthcare and personalized medicine becomes increasingly evident.

2. Nanocarriers in Drug Delivery Systems:

Nanocarriers are nanoscale materials that are used to encapsulate or carry therapeutic agents, such as small molecules, proteins, or genes, to their target site. These carriers can be engineered to improve drug delivery by overcoming biological barriers, controlling the release of drugs, and targeting specific tissues or cells. Several types of nanocarriers are being investigated for drug delivery applications, including:

2.1. Liposomes

Liposomes are spherical vesicles made of lipid bilayers that can encapsulate both hydrophilic and hydrophobic drugs. Their biocompatibility, ability to carry both small molecules and macromolecules, and their potential for controlled release have made liposomes one of the most widely researched nanocarriers.



They typically range from 20 nanometers to several micrometers in diameter and can be composed of various phospholipids, which allow for the formation of a bilayer structure similar to biological membranes. Due to their ability to encapsulate both hydrophilic and hydrophobic substances, liposomes can be engineered to improve the solubility, stability, and bioavailability of therapeutic agents. Their biocompatibility and ability to fuse with cell membranes facilitate targeted drug delivery, minimizing side effects and enhancing therapeutic efficacy. Liposomes can be modified with specific ligands or antibodies to achieve selective targeting of diseased tissues, such as cancer cells, thereby improving treatment outcomes. Additionally, liposomes are utilized in vaccines, cosmetic formulations, and as carriers for nucleic acids in gene therapy, highlighting their versatility in various fields of medicine and biotechnology.

Types of liposomes based on size:
a)Small Unilamellar Vesicles (SUV):
Diameter between 20-100 nm.

b)Large Unilamellar Vesicles (LUV):
Diameter between 100-1000 nm.

c)Giant Unilamellar Vesicles (GUV):
Diameter greater than 1,000 nm.

d)Multilamellar Vesicles (MLV):
Typically larger and composed of several lipid bilayers.

2.2. Solid Lipid Nanoparticles (SLNs):

SLNs consist of a solid lipid core and a surfactant layer, offering controlled drug release, enhanced stability, and the ability to carry both hydrophilic and lipophilic drugs. They are particularly useful for the sustained release of drugs and are considered more stable than liposomes.



Key features of SLNs:
Composition: Typically consist of solid lipids (e.g., glyceryl monostearate, stearic acid) stabilized by surfactants.
Size: They range from 50 nm to 1000 nm.
Advantages: Non-toxic, stable, can encapsulate both hydrophilic and hydrophobic drugs, and offer controlled drug release.
Applications: Used in cancer therapy, gene delivery, vaccine delivery, and treatment of infectious diseases.

2.3. Polymeric Nanoparticles:

Polymeric nanoparticles, made from biodegradable and biocompatible polymers, are one of the most promising carriers for drug delivery. They can be designed to release drugs in response to specific environmental triggers (e.g., pH, temperature, or enzymes) and can also be engineered for targeted delivery.
PNPs can be classified into two main types:
a)Nanospheres: These are solid, spherical particles where the drug is uniformly dispersed within the polymer matrix. Nanospheres offer controlled release mechanisms, as the drug is slowly released from the polymer matrix.
b)Nanocapsules: These have a hollow core, which encapsulates the drug inside the polymeric shell. Nanocapsules are particularly useful for drugs that require protection from environmental conditions or for prolonged release at specific sites.



2.4. Dendrimers

Dendrimers are highly branched, tree-like macromolecules that provide a high surface area for drug loading. Their unique structure allows for the encapsulation of both hydrophilic and hydrophobic drugs and can be functionalized for specific targeting.



They consist of a central core, branching units called generations, and terminal functional groups that extend outward. The structure of dendrimers resembles a tree with a trunk (the core) and branches (the generations). Each generation introduces new layers of branching, which increases the size and functionality of the dendrimer. The outer surface of dendrimers is functionalized with a variety of chemical groups that can be tailored to specific applications, such as drug delivery, gene therapy, imaging, and sensing. One of the most significant properties of dendrimers is their monodispersity, meaning they are uniform in size and shape, which is critical for applications requiring precise molecular control. Their high surface area allows for the attachment of a large number of functional groups, making them ideal candidates for use in various fields.

2.5. Nanotubes and Nanofibers :

Carbon nanotubes (CNTs) and nanofibers have exceptional mechanical properties and surface areas that allow them to be used as drug carriers. They can deliver a wide range of drugs, including anticancer agents, and can be modified for targeted delivery.particularly carbon nanotubes (CNTs), are cylindrical structures with diameters typically in the range of a few nanometers and lengths extending to micrometers or even millimeters. These tubes are composed of carbon atoms arranged in a hexagonal lattice, which gives them exceptional mechanical strength, electrical conductivity, and thermal properties. Carbon nanotubes are categorized into single-walled nanotubes (SWCNTs) and multi-walled nanotubes (MWCNTs), depending on the number of concentric graphene layers. Due to their high tensile strength, conductivity, and unique surface chemistry, CNTs are used in a wide range of applications, including electronics, materials science, energy storage, and medicine. Nanofibers, on the other hand, are fibers with diameters in the nanometer range (typically less than 100 nm) and can be made from a variety of materials, including polymers, metals, ceramics, and carbon. They can be produced through several techniques, such as electrospinning, which involves using an electric field to draw polymer solutions into thin fibers. Nanofibers have a very high surface area to volume ratio, which enhances their mechanical, chemical, and thermal properties. Their small size, combined with their large surface area, makes them ideal for applications in filtration, tissue engineering, sensors, and energy storage devices. Unlike nanotubes, which typically have a hollow core, nanofibers can be solid or have a porous structure, offering additional versatility for various applications.

3. Targeted Drug Delivery:

A major advantage of nanotechnology in drug delivery is the ability to target specific cells or tissues, reducing off-target effects and improving the therapeutic index of drugs. Targeting strategies include:

3.1. Active Targeting

Active targeting involves modifying nanocarriers with targeting ligands (e.g., antibodies, peptides, or small molecules) that bind to specific receptors on the surface of target cells. This approach improves the precision of drug delivery and reduces the amount of drug required, thus minimizing side effects.

3.2. Passive Targeting

Passive targeting takes advantage of the natural properties of nanoparticles, such as their size, surface charge, and the enhanced permeability and retention (EPR) effect. The EPR effect refers to the increased accumulation of nanoparticles in tumor tissues due to leaky vasculature. This mechanism is widely used for cancer therapy.

3.3. pH-Responsive Drug Delivery

Some nanocarriers can be engineered to release their payload in response to the acidic environment found in certain tissues, such as tumors or inflamed areas. These systems can be designed to remain stable in the bloodstream and release the drug only when they reach the target site.

3.4. Enzyme-Responsive Systems

Certain nanocarriers can be modified to respond to specific enzymes that are overexpressed in diseased tissues. This strategy is particularly useful for targeted delivery of drugs to areas with high enzyme activity, such as tumors.

Mechanisms of Drug Release:

Nanotechnology-based DDS allows for the controlled release of therapeutic agents. The mechanisms of drug release from nanoparticles includes

4.1. Diffusion-Controlled Release

Drugs are released from the nanocarrier through diffusion over time. This is typically seen in systems like liposomes or SLNs, where the drug is slowly released into the surrounding environment.

4.2. Degradation-Controlled Release

The nanocarrier itself undergoes degradation, leading to the release of the drug. This can be done through the hydrolysis of polymeric chains, enzymatic degradation, or the breakdown of lipid-based materials.

4.3. Triggered Release

Certain nanocarriers are designed to release the drug in response to external or internal stimuli, such as changes in pH, temperature, or the presence of specific enzymes. This approach allows for more precise control of when and where the drug is released.

Clinical Applications:

Nanotechnology-based drug delivery systems are already being explored and utilized in various clinical settings:

5.1. Cancer Therapy

Nanocarriers are extensively used in cancer therapy to improve the solubility and targeting of anticancer drugs. Liposomal formulations, such as Doxil (liposomal doxorubicin), have been approved for clinical use. Nanoparticles can deliver chemotherapy drugs directly to tumors, reducing the systemic toxicity and improving therapeutic outcomes.

5.2. Gene Therapy

Nanotechnology has facilitated the delivery of genetic materials, such as DNA and RNA, for gene therapy applications. Nanoparticles can protect genetic material from degradation and facilitate its delivery to specific cells or tissues.

6. Challenges and Future Directions :

1. Despite the promising potential of nanotechnology in drug delivery, several challenges remain: Toxicity and Biocompatibility: The long-term safety of nanomaterials needs to be carefully evaluated. Some nanoparticles may cause toxicity, inflammation, or immune reactions.
2. Scalability and Manufacturing: The production of nanocarriers at a large scale while maintaining quality control remains a significant hurdle.
3. Regulatory Issues: The approval process for nanomedicines is still evolving, and clear guidelines for their evaluation and clinical use are needed.
4. Cost: The high cost of nanotechnology-based DDS may limit their widespread adoption, especially in low-resource settings.

Future research will focus on addressing these challenges while improving the precision and effectiveness of nanotechnology-based drug delivery systems. Innovations in nanomaterials, biocompatibility, and targeting strategies hold great promise for the future of drug delivery.

REFERENCES:

1. S. J. Lee, et al. (2023). "Nanotechnology in Drug Delivery: Current Trends and Future Perspectives." Journal of Nanomedicine.

2. A. Gupta, et al. (2022). "Targeted Drug Delivery: Principles and Applications." Advanced Drug Delivery Reviews.
3. R. Singh, et al. (2023). "Biodegradable Drug Delivery Systems: Recent Advances." Biomaterials Science.
4. J. K. Park, et al. (2023). "Smart Drug Delivery Systems: A Review." Materials Today
5.Nilesh J, Ruchi J, Navneet T, Brham Prakash G, Deepak kumar J. Nanotechnology: A Safe And Effective Drug Delivery Systems. Asian Journal of Pharmaceutical and Clinical Research 2010, vol.3, issue 3. 159-165.
6. Rakesh P.P. Nanoparticles and its Applications in Field of Pharmacy. Available at http://www. Pharmainfo.net/reviews/Nanoparticles-and-its-applications-field-phamacy.2008.
7. Herbert A. L, Martin M. R, Gilbert S. B (2005). Pharmaceutical dosage forms: Disperse Systems. Vol.3, Marcel dekker, inc, 2nd Edition. 88-105.
8. Eric A, Robert G, Eric D. Drug-Loded Nanoparticle Preparation Methods and Drug Targeting Issues. Eur.j.Pharm.Biopharm., (1993), 39(5) 173-91.
9. Harsimran K, Archana C, Inderpreet K, Kashmir S, Lalit M.B.(2010)Transportation of Drug- Gold Nanocomposites by Actinomyosin Motor System. Journal of Nanoparticle Research.
10. Gupta S, Viyas SP: Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. J Drug Target 2007, 15(3):206-217.
11. Hynes RO: A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002, 8:918-921.
12. Hynes RO, Zhao Q: The evolution of cell adhesion. J Cell Biol 2000, 24:F89-F96.
13. Chen X, Plasencia C, Hou Y, Neamati N: Synthesis and biological evaluation of dimeric RGD peptide-Paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem 2005, 48:1098-1106.
14. Gupta AS, Huang G, Lestini BJ, Sagnella S, Kottke-Marchant K, Marchant RE: RGD modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb Haemost 2005, 93:106-114.
15. Schiffelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, Kok RJ, Molema G, Strom G: Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Rel 2003, 91:115-122.
16. Haass NK, Smalley KS, Li L, Herlyn M: Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res 2005, 18:150-159.
17. Christofori G: Changing neighbours, changing behaviour: Cell adhesion molecule-mediated signalling during tumour progression. EMBO J 2003, 22:2318-2323.
18. Pancioli AM, Brott TG: Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke: Scientific rationale and available evidence. CNS Drugs 2004, 18:981-988.
19. Andrews RK, Berndt MC: Platelet physiology and thrombosis. Thromb Res 2004, 114:447-453.
20. Anderson ME, Siahaan TJ: Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: Designing peptide and small molecule inhibitors. Peptides 2003, 24:487-501.
21. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ: Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 2002, 22:146-167.
22. Shimaoka M, Springer TA: Therapeutic antagonists and the conformational regulation of the β2 integrins. Curr Top Med Chem 2004, 4:1485-1495.
23. Arap W, Pasqualini RR, Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
24. Zhuang S, Schnellmann RG: A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 2006, 319:991-997.
25. Dunehoo AL, Anderson M, Majumdar S, Kobayashi N, Berkland C, Siahaan TJ: Cell adhesion molecules for targeted drug delivery. J pharmaceutical Sci 2006, 95:1856-1872.
26. Zhang N, Berkland C: Synthesis of PLGA Nanoparticles with Conjugated CLABL as Targeted Vascular Delivery Vehicles. Science Talks, Higuchi Biosciences Center, University of Kansas, Lawrence; 2006.